Company Hemispherx BioPharma, Inc Nyse
Equities
US42366C3016
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Ampligen and Other Drugs
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +43.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +43.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 | |
Peter Rodino
COO | Chief Operating Officer | 72 | 13-07-22 |
David R. Strayer
CTO | Chief Tech/Sci/R&D Officer | 78 | 85-12-31 |
Jenene Thomas
IRC | Investor Relations Contact | 52 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
William Mitchell
CHM | Chairman | 89 | 98-06-30 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Peter Rodino
COO | Chief Operating Officer | 72 | 13-07-22 |
Director/Board Member | 70 | 16-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,888,333 | 46,402,300 ( 91.18 %) | 0 | 91.18 % |
Stock B | 0 | 689 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |